Plain-English translation of NCT07607197 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a procedure called (AHSCT) to help patients with kidney failure who have developed strong immune responses against donor kidneys. The procedure uses medications to quiet your immune system, then collects and reinfuses your own stem cells to essentially reset your immune system. The goal is to make it possible for these patients to receive a compatible kidney transplant after their immune response has been reduced.
Some patients waiting for a kidney transplant have developed antibodies against many types of donor kidneys, making it extremely difficult to find a match. This trial exists to see whether resetting the immune system through stem cell transplantation can safely reduce these antibodies and give highly sensitized patients a real chance at receiving a life-saving kidney transplant.
You likely qualify if…
You likely don't qualify if…
If accepted, you would receive medications intravenously to quiet your immune system and prepare your body. Your stem cells would then be collected from your blood through a process called leukapheresis, specially selected, and reinfused back into you. After the procedure, you would be monitored closely for 12 months, with blood and bone marrow samples taken at regular intervals to track how your immune system recovers. At 6 months, if all is going well, you would be put back on the kidney transplant waiting list and could receive a compatible kidney when one becomes available.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Spain